Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Non-small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Strategies
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Non-small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Strategies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 3959

Special Issue Editor

Dr. Lorenzo Belluomini

E-Mail Website
Guest Editor
Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy
Interests: NSCLC; immunotherapy

Special Issue Information

Dear Colleagues,

In the modern era, the treatment landscape for non-small cell lung cancer (NSCLC) has undergone a significant transformation due to the introduction of Immune checkpoint inhibitors (ICIs), either alone or in combination with chemotherapy, and targeted therapies (TT) both in early and advanced stages. Additionally, novel treatment options, such as antibody–drug conjugates (ADCs), offer new possibilities in the fight against lung cancer. Precision oncology plays a critical role in guiding treatment decisions, not only based on the molecular profile of the tumor at baseline but also considering molecular/histological changes at disease progression. Extensive efforts have been made in recent decades to evaluate the efficacy and safety of current treatment strategies, particularly ICIs, in "special populations" such as elderly patients, those with poor ECOG performance status, and those with comorbidities like chronic viral infections.

This Special Issue aims to gather original and review articles that focus on assessing the efficacy and safety of current and novel therapies in both oncogene-addicted and non-oncogene-addicted NSCLC, as well as the evaluation of potential predictive and prognostic molecular biomarkers. We encourage authors to submit original or review articles that investigate the role of novel treatments in "special populations" affected by NSCLC in order to enhance our understanding of their impact in these patient subgroups.

Dr. Lorenzo Belluomini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NSCLC
  • predictive and prognostic biomarkers
  • immunotherapy
  • targeted therapy
  • special populations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2017 KiB  
Article
Oncogenic KRASG12D Transfer from Platelet-like Particles Enhances Proliferation and Survival in Non-Small Cell Lung Cancer Cells
by Jorge Ceron-Hernandez, Gonzalo Martinez-Navajas, Jose Manuel Sanchez-Manas, María Pilar Molina, Jiajun Xie, Inés Aznar-Peralta, Abel Garcia-Diaz, Sonia Perales, Carolina Torres, Maria J. Serrano and Pedro J. Real
Int. J. Mol. Sci. 2025, 26(7), 3264; https://doi.org/10.3390/ijms26073264 - 1 Apr 2025
Viewed by 475
Abstract
In the tumor context, platelets play a significant role in primary tumor progression, dissemination and metastasis. Analysis of this interaction in various cancers, such as non-small cell lung cancer (NSCLC), demonstrate that platelets can both transfer and receive biomolecules (e.g. RNA and proteins) [...] Read more.
In the tumor context, platelets play a significant role in primary tumor progression, dissemination and metastasis. Analysis of this interaction in various cancers, such as non-small cell lung cancer (NSCLC), demonstrate that platelets can both transfer and receive biomolecules (e.g. RNA and proteins) to and from the tumor at different stages, becoming tumor-educated platelets. To investigate how platelets are able to transfer oncogenic material, we developed in vitro platelet-like particles (PLPs), from a differentiated MEG-01 cell line, that stably carry RNA and protein of the KRASG12D oncogene in fusion with GFP. We co-cultured these PLPs with NSCLC H1975 tumor cells to assess their ability to transfer this material. We observed that the generated platelets were capable of stably expressing the oncogene and transferring both its RNA and protein forms to tumor cells using qPCR and imaging techniques. Additionally, we found that coculturing PLPs loaded with GFP-KRASG12D with tumor cells increased their proliferative capacity at specific PLP concentrations. In conclusion, our study successfully engineered an MEG-01 cell line to produce PLPs carrying oncogenic GFP-KRASG12D simulating the tumor microenvironment, demonstrating the efficient transfer of this oncogene to tumor cells and its significant impact on enhancing proliferation. Full article
(This article belongs to the Special Issue Non-small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Strategies)
►▼ Show Figures

Figure 1

21 pages, 16306 KiB  
Article
Human Non-Small Cell Lung Cancer-Chicken Embryo Chorioallantoic Membrane Tumor Models for Experimental Cancer Treatments
by Jing Li, Tereza Brachtlova, Ida H. van der Meulen-Muileman, Stijn Kleerebezem, Chang Liu, Peiyu Li and Victor W. van Beusechem
Int. J. Mol. Sci. 2023, 24(20), 15425; https://doi.org/10.3390/ijms242015425 - 21 Oct 2023
Cited by 2 | Viewed by 2561
Abstract
To promote the preclinical development of new treatments for non-small cell lung cancer (NSCLC), we established NSCLC xenograft tumor assays on the chorioallantoic membrane (CAM) of chicken embryos. Five NSCLC cell lines were compared for tumor take rate, tumor growth, and embryo survival. [...] Read more.
To promote the preclinical development of new treatments for non-small cell lung cancer (NSCLC), we established NSCLC xenograft tumor assays on the chorioallantoic membrane (CAM) of chicken embryos. Five NSCLC cell lines were compared for tumor take rate, tumor growth, and embryo survival. Two of these, A549 and H460 CAM tumors, were histologically characterized and tested for susceptibility to systemic chemotherapy and gene delivery using viral vectors. All cell lines were efficiently engrafted with minimal effect on embryo survival. The A549 cells formed slowly growing tumors, with a relatively uniform distribution of cancer cells and stroma cells, while the H460 cells formed large tumors containing mostly proliferating cancer cells in a bed of vascularized connective tissue. Tumor growth was inhibited via systemic treatment with Pemetrexed and Cisplatin, a chemotherapy combination that is often used to treat patients with advanced NSCLC. Lentiviral and adenoviral vectors expressing firefly luciferase transduced NSCLC tumors in vivo. The adenovirus vector yielded more than 100-fold higher luminescence intensities after a single administration than could be achieved with multiple lentiviral vector deliveries. The adenovirus vector also transduced CAM tissue and organs of developing embryos. Adenovirus delivery to tumors was 100–10,000-fold more efficient than to embryo organs. In conclusion, established human NSCLC-CAM tumor models provide convenient in vivo assays to rapidly evaluate new cancer therapies, particularly cancer gene therapies. Full article
(This article belongs to the Special Issue Non-small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop